Danish Insurance Stock News

Recent share performance and business scale ISS (CPSE:ISS) has caught investor attention after a strong year, with the stock showing a 65.1% total return over the past 12 months and 21.9% year to date. Over the past week the share price return is 10.1%, with gains of 8.9% over the past month and 4.8% over the past 3 months. The company reports DKK 84,684 million in revenue and DKK 2,603 million in net income. See our latest analysis for ISS. With ISS shares now trading at DKK262.8 and showing...

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...

We wouldn't blame Danske Bank A/S ( CPH:DANSKE ) shareholders if they were a little worried about the fact that Carsten...

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...

Why Vestas Wind Systems is back on investors’ radar Vestas Wind Systems (CPSE:VWS) is drawing fresh attention after reporting first quarter 2026 earnings, with sales of €3,966 million and net income of €82 million, alongside confirmed full year revenue and margin guidance. The update also arrived alongside new turbine orders in Germany, giving investors fresh information on both current profitability and the future project pipeline for one of the sector’s established wind equipment...

Why the JCSI-35 launch matters for NKT stock NKT (CPSE:NKT) has drawn fresh investor attention after introducing its IEEE-qualified JCSI-35 medium-voltage cold-shrink splice in North America, a product aimed at grid operators across the United States and Canada. The launch ties directly to NKT’s effort to grow its accessories offering in a copper wire and cable market that is projected to expand, as well as reinforcing its role in large infrastructure projects such as Champlain Hudson Power...

MT Højgaard Holding (CPSE:MTHH) has put fresh numbers on the table for FY 2025, with Q4 revenue of DKK 2.5b and basic EPS of DKK 10.08 alongside net income from continuing operations of DKK 77.7m. Over recent quarters the company has seen revenue move between DKK 2.4b and DKK 3.1b and quarterly EPS range from DKK 9.13 to DKK 14.81, which sets expectations around how a trailing net margin of 3.1% will shape investor views on the quality and resilience of those earnings. See our full analysis...

Q1 earnings as the key trigger Novozymes (CPSE:NSIS B) is back in focus after reporting first quarter 2026 results, with sales of €1,119.3 million and net income of €199.1 million compared with the same period a year earlier. See our latest analysis for Novozymes. The Q1 release appears to have steadied sentiment, with a 1-day share price return of 2.25% partly offsetting weaker recent momentum, including a 1-year total shareholder return of 12.68% and a 5-year total shareholder return of...

Genmab (CPSE:GMAB) has drawn fresh attention after its first quarter 2026 report, where sales reached US$896 million but net income dropped to US$53 million, alongside a negative immediate share price reaction. See our latest analysis for Genmab. The weak 1 day share price return of 6.74% and 30 day share price return of 8.30% follow a Q1 update where revenue moved higher but net income declined sharply, leaving the current share price at DKK1,640. Over a longer horizon, the 1 year total...

Why Vizient’s contract matters for Coloplast (CPSE:COLO B) Coloplast (CPSE:COLO B) just secured an Innovative Technology contract with Vizient for its Biatain Silicone Fit wound dressing, putting the product in front of a broad network of US hospitals and care providers. This recognition reflects feedback from Vizient’s client-led councils and signals that Biatain Silicone Fit has characteristics US healthcare buyers consider differentiating. This development could influence how investors...

If you are wondering whether Pandora at DKK 537.6 is priced for a recovery or still carries more risk than reward, this breakdown will help you frame what the current share price might be implying. The stock has returned 8.2% over the last week and 14.0% over the last month, set against a year-to-date return of a 22.7% decline and a 45.4% decline over the last year. Recent coverage around Pandora has focused on whether the current share price aligns with its fundamentals, as investors weigh...

A.P. Møller & Co. Mærsk (CPSE:MAERSK B) is back in focus after first quarter 2026 results showed profit pressure alongside higher fuel and operating costs linked to Middle East disruptions, including the war in Iran and constrained shipping routes. See our latest analysis for A.P. Møller - Mærsk. The stock has pulled back recently, with a 7 day share price return of 7.22% and a 30 day share price return of 11.34% after the weaker Q1 net income and rising fuel costs. However, the 1 year total...

Shareholders might have noticed that Ørsted A/S ( CPH:ORSTED ) filed its quarterly result this time last week. The...

Shareholders might have noticed that GN Store Nord A/S ( CPH:GN ) filed its first-quarter result this time last week...

As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...

Why Jyske Bank’s latest earnings matter for shareholders Jyske Bank (CPSE:JYSK) just released first quarter 2026 results, giving you fresh insight into how the bank is handling weaker net interest income and net income while keeping capital and fee income on a firm footing. See our latest analysis for Jyske Bank. Despite the softer Q1 figures, the stock’s 1 year total shareholder return of 56.04% and 5 year total shareholder return of 217.03% contrast with a recent 9.49% 3 month share price...

Novo Nordisk recently reported first‑quarter 2026 results showing sales rising to DKK 96,823 million and net income to DKK 48,557 million, driven largely by surging demand for its new oral Wegovy weight‑loss pill, which has passed two million U.S. prescriptions since its January launch. This launch is being described as the strongest-ever U.S. obesity drug debut by volume, prompting Novo Nordisk to raise its 2026 guidance for adjusted sales and operating profit as oral GLP‑1 treatments...

Genmab (CPSE:GMAB) opened 2026 with Q1 revenue of US$896 million and basic EPS of US$0.84, setting the tone for how the market will judge its current earnings run versus earlier quarters. Over the past year, reported quarterly revenue has ranged from US$715 million to just over US$1.0 billion, while basic EPS has moved between US$0.50 and US$9.10. This gives you a wide band of outcomes to weigh against the trailing 12 month EPS of US$13.24 and net income of US$821 million. With net margins in...

Solar (CPSE:SOLAR B) has opened 2026 with Q1 revenue of DKK 3.3b and a basic EPS loss of DKK 5.28, while the trailing twelve months show EPS of DKK 7.81 on revenue of DKK 12.3b and net income of DKK 59m. This sets a mixed backdrop for the latest release. Over recent quarters, the company has seen revenue move from DKK 3.2b in Q1 2025 to DKK 3.3b in Q1 2026, with quarterly EPS swinging between a profit of DKK 12.99 in Q4 2025 and a loss of DKK 5.28 in the latest period. With net profit margins...

The quarterly results for Netcompany Group A/S ( CPH:NETC ) were released last week, making it a good time to revisit...

Shareholders of Pandora A/S ( CPH:PNDORA ) will be pleased this week, given that the stock price is up 12% to kr.541...

Vestas Wind Systems A/S ( CPH:VWS ) just released its quarterly report and things are looking bullish. The company beat...

Zealand Pharma (CPSE:ZEAL) opened Q1 2026 with revenue of DKK 34 million, a basic EPS loss of DKK 5.58 and net income loss of DKK 394 million, setting a very different tone against the backdrop of a trailing twelve month EPS of DKK 90.74 and net income of DKK 6.4b. Over recent quarters the company has seen revenue move from DKK 8.09 million in Q1 2025 to DKK 9.06 million in Q4 2024 and then up to DKK 9.09b in Q2 2025, while quarterly EPS has swung from a loss of DKK 4.11 in Q4 2024 to a...

Trifork Group AG ( CPH:TRIFOR ) just released its latest first-quarter report and things are not looking great. It...